Rigel Pharmaceuticals Inc. (New)
RIGLRigel Pharmaceuticals Inc. (RIGL) is a biotechnology company focused on discovering and developing targeted therapies for underserved disease areas, primarily in immunology, oncology, and rare diseases. Founded in 1997, the company leverages its expertise in kinase inhibition and intracellular signaling to develop innovative medications aimed at improving patient outcomes. Rigel's portfolio includes both approved drugs and promising clinical-stage candidates.
Company News
Rigel Pharmaceuticals exceeded Q2 2025 financial expectations with 176.4% revenue growth, driven by strong product sales and a significant Eli Lilly collaboration, raising full-year revenue guidance to $270-$280 million.
Knight Therapeutics, a specialty pharmaceutical company, announced that its Mexican subsidiary has obtained regulatory approval from COFEPRIS for TAVALISSE® (fostamatinib) to treat adult patients with chronic immune thrombocytopenia (ITP) whose response to prior treatment was insufficient.
The article discusses the T-cell lymphoma drug pipeline, highlighting the development of novel therapies by companies like Eisai, Takeda, and Rhizen Pharmaceuticals. Regulatory agencies are providing support to accelerate the development of these treatments, addressing the urgent need for better options in this challenging condition.
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel (RIGL) delivered earnings and revenue surprises of -66.67% and 5.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
